In conclusion, SS-d effectively controls the proliferation of hepatocellular carcinoma cells by inhibiting the p-STAT3/C/EBPβ signaling pathway and reducing the expression of COX-2, thereby reinforcing its potential application in the treatment of hepatocellular carcinoma. Here, STAT3 is linked to hepatocellular carcinoma.